Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curdepsidone A is a natural depsidone isolated from the marine-derived endophytic fungus Curvularia sp. IFB-Z10. It exhibits potent anti-tumor activity, particularly against human cervical cancer cells (HeLa), where it induces G0/G1 phase cell cycle arrest and promotes apoptosis through the mitochondrial pathway. Its mechanism involves inhibition of protective autophagy, elevation of intracellular reactive oxygen species (ROS), and suppression of PI3K/AKT signaling. These combined actions lead to anti-proliferative and pro-apoptotic effects in various tumor cell lines, with the greatest sensitivity seen in HeLa cells. Structure revision and mechanistic studies suggest potential for development as a chemotherapy agent for cervical cancer[1][3][5][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curdepsidone A.